Ian N. Boys

Ian N. Boys

Auto-generated profile, based on publicly available information

Ian N. Boys

Department of Microbiology, University of Texas Southwestern Medical Center

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2020 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
SPStephanie Pfaender
Stephanie Pfaender
KMKatrina B. Mar
Katrina B. Mar
EMEleftherios Michailidis
Eleftherios Michailidis
AKAnnika Kratzel
Annika Kratzel
IBIan N. Boys
Ian N. Boys
VTVolker Thiel
Volker Thiel

17 September 2018 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
RRR. Blake Richardson
R. Blake Richardson
MOMaikke B. Ohlson
Maikke B. Ohlson
JEJennifer L. Eitson
Jennifer L. Eitson
AKAshwani Kumar
Ashwani Kumar
MMMatthew B. McDougal
Matthew B. McDougal
JSJohn Schoggins
John Schoggins

6 September 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
KMKatrina B. Mar
Katrina B. Mar
NRNicholas R. Rinkenberger
Nicholas R. Rinkenberger
IBIan N. Boys
Ian N. Boys
JEJennifer L. Eitson
Jennifer L. Eitson
MMMatthew B. McDougal
Matthew B. McDougal
JSJohn Schoggins
John Schoggins
Interferons (IFNs) contribute to cell-intrinsic antiviral immunity by inducing hundreds of interferon-stimulated genes (ISGs). In a screen to identify antiviral ISGs, we unexpectedly found that LY6E, a member of the LY6/uPAR family, enhanced viral infection. Here, we show that viral enhancement by ectopically expressed LY6E extends to several cellular backgrounds and affects multiple RNA viruses. LY6E does not impair IFN antiviral activity or signaling, but rather promotes viral entry. Using influenza A virus as a model, we narrow the enhancing effect of LY6E to uncoating after endosomal escape. Diverse mammalian orthologs of LY6E also enhance viral infectivity, indicating evolutionary conservation of function. By structure-function analyses, we identify a single amino acid in a predicted loop region that is essential for viral enhancement. Our study suggests that LY6E belongs to a class of IFN-inducible host factors that enhance viral infectivity without suppressing IFN antiviral activity.

3 December 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
NHNatasha W. Hanners
Natasha W. Hanners
KMKatrina B. Mar
Katrina B. Mar
IBIan N. Boys
Ian N. Boys
JEJennifer L. Eitson
Jennifer L. Eitson
PCPamela C. De La Cruz-Rivera
Pamela C. De La Cruz-Rivera
JSJohn Schoggins
John Schoggins
Significance: Flaviviruses are significant human pathogens and emerging infectious disease threats. A screen of interferon-inducible genes revealed Shiftless (SHFL) as a potent antiviral effector, inhibiting all Flaviviridae tested, including West Nile, Zika, dengue, yellow fever, and hepatitis C viruses. Mechanistic studies showed that SHFL inhibits viral replication at a point after translation of the incoming genome. In whole-body Shfl knockout (KO) mice, compared to wild-type mice, the Shfl KO mice were more susceptible to Zika virus. Notably, Shfl was uniquely required for controlling replication in the brain and spinal cord, demonstrating an unappreciated neuroprotective role for this effector in vivo. SHFL is a key antiviral effector that specifically inhibits flavivirus genome replication, and Shfl protects mice from Zika virus–induced neuropathogenesis.

20 May 2021 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
IBIan N. Boys
Ian N. Boys
KMKatrina B. Mar
Katrina B. Mar
JSJohn Schoggins
John Schoggins
The Receptor Transporter Protein (RTP) family is present in most, if not all jawed vertebrates. Most of our knowledge of this protein family comes from studies on mammalian RTPs, which are multi-function proteins that regulate cell-surface G-protein coupled receptor levels, influence olfactory system development, regulate immune signaling, and directly inhibit viral infection. However, mammals comprise less than one-tenth of extant vertebrate species, and our knowledge about the expression, function, and evolution of non-mammalian RTPs is limited. Here, we explore the evolutionary history of RTPs in vertebrates. We identify signatures of positive selection in many vertebrate RTP clades and characterize multiple, independent expansions of the RTP family outside of what has been described in mammals. We find a striking expansion of RTPs in the African clawed frog, Xenopus laevis, with 11 RTPs in this species as opposed to 1 to 4 in most other species. RNA sequencing revealed that most X. laevis RTPs are upregulated following immune stimulation. In functional assays, we demonstrate that at least three of these X. laevis RTPs inhibit infection by RNA viruses, suggesting that RTP homologs may serve as antiviral effectors outside of Mammalia.

22 October 2025 in eLife
Verified
Journal Article
Open access
MMMatthew B McDougal
Matthew B McDougal
IBIan N Boys
Ian N Boys
AMAnthony M De Maria
Anthony M De Maria
ENEmi Nakahara
Emi Nakahara
JSJohn Schoggins
John Schoggins
Mammalian mRNAs possess an N7-methylguanosine (m7G) cap and 2'O methylation of the initiating nucleotide at their 5' end, whereas certain viral RNAs lack these characteristic features. The human antiviral restriction factor IFIT1 recognizes and binds to specific viral RNAs that lack the 5' features of host mRNAs, resulting in targeted suppression of viral RNA translation. This interaction imposes significant host-driven evolutionary pressures on viruses, and many viruses have evolved mechanisms to evade the antiviral action of human IFIT1. However, little is known about the virus-driven pressures that may have shaped the antiviral activity of IFIT1 genes across mammals. Here, we take an evolution-guided approach to show that the IFIT1 gene is rapidly evolving in multiple mammalian clades, with positive selection acting upon several residues in distinct regions of the protein. In functional assays with 39 IFIT1s spanning diverse mammals, we demonstrate that IFIT1 exhibits a range of antiviral phenotypes, with many orthologs lacking antiviral activity against viruses that are strongly suppressed by other IFIT1s. We further show that IFIT1s from human and a bat, the black flying fox, inhibit Venezuelan equine encephalitis virus (VEEV) and strongly bind to Cap0 RNAs. Unexpectedly, chimpanzee IFIT1, which differs from human IFIT1 by only eight amino acids, does not inhibit VEEV infection and exhibits minimal Cap0 RNA-binding. In mutagenesis studies, we determine that amino acids 364 and 366, the latter of which is rapidly evolving, are sufficient to confer the differential anti-VEEV activity between human and chimpanzee IFIT1. These data suggest that virus-host genetic conflicts have influenced the antiviral specificity of IFIT1 across diverse mammalian orders.